drugset / Trial / NCT02812433

Sildenafil Administration to Treat Neonatal Encephalopathy

NCT02812433

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Despite improvements in neonatal care, birth asphyxia in term newborns remains a serious condition causing significant mortality and long-term morbidity, including cerebral palsy and mental retardation. Currently, no treatment exists to repair brain injuries secondary to neonatal asphyxia. The only available treatment for this condition is hypothermia that may prevent but not repair the development of brain injury. The success of this therapy is limited. Sildenafil already is used with some newborns for other purposes (i.e., persistent pulmonary hypertension), but, surprisingly, its effect on the newborn brain has never been studied systematically. The findings of the investigators in the rat model of term neonatal encephalopathy demonstrated that the administration of sildenafil following asphyxia promotes brain injury recovery. Thus, the investigators hypothesize that sildenafil may improve neurodevelopmental outcome in term asphyxiated newborns, in whom hypothermia treatment has failed to prevent the development of brain injury.

Timeline

Start
2016-07
Primary completion
2019-01
Completion
2022-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sildenafil Unknown 2 mg/kg Oral

Indications

No indication recorded.